tirzepatide for heart failure with preserved ejection fraction and obesity SUMMIT: Improves Outcomes Quality of Life Patients HFpEF and Association of Tirzepatide Use With

Many patients are on a combination of an SGLT2 inhibitor with a GLP-1 receptor agonist or tirzepatide (a dual agonist) and have incredible success without adverse reactions, but we are still figuring out the patient characteristics that would put them at higher risk of poor outcomes. Eli J

Genetic variants that youre born with can increase the susceptibility to polycythemia vera in a couple of ways: Recent research shows that common inherited variants can increase the susceptibility to having a JAK2 somatic mutation.[ref] These common JAK2 changes make it slightly more likely that a mutation can arise in the gene

10.1139/y87-317 [DOI] [PubMed] [Google Scholar] Shapouri-Moghaddam A., Mohammadian S., Vazini H., Taghadosi M., Esmaeili S., Mardani F., et al

GLP-1 Medications Opened a Door